AbGenomics Corporation
2F, No. 36, Ln. 358, Juikuang Road
Neihu
Taipei
114
Tel: 886-2-2627-2707
Fax: 886-2-2627-2708
Website: http://www.abgenomics.com/
Email: contact@abgenomics.com
10 articles about AbGenomics Corporation
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
-
AbGenomics Corporation Announces FDA Acceptance To Commence Phase I Clinical Trial Of Abgn-107 ADC Candidate For Pancreatic, Gastric, And Colorectal Cancer Treatments
8/15/2016
-
AbGenomics Corporation Announces Initiation Of Phase-Ib/Iia Clinical Trial Of Neihulizumab (AbGn-168H) For The Treatment Of Steroid Refractory Acute GvHD (aGvHD)
5/18/2015
-
AbGenomics Corporation Announces IND Filing For Abgn-168H (Neihulizumab) To Treat Psoriatic Arthritis
10/17/2014
-
Los Altos' AbGenomics Corporation Locks In $16 Million
10/6/2014
-
AbGenomics Corporation Has Raised $9.6 Million for Advancing Its Psoriasis Phase-II Trials in U.S.
7/18/2013
-
AbGenomics Corporation Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
8/20/2012
-
AbGenomics Corporation Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
8/20/2012
-
AbGenomics Corporation Regains Global Rights to AbGn-168H from Boehringer Ingelheim Corporation
12/19/2011
-
Crucell N.V. And DSM Biologics Announce PER.C6(R) License Agreement With AbGenomics Corporation
1/11/2007